13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • MK3475-641

    Acronym: 

    KEYNOTE 641

    ACTRN/NCT /ethics: 

    Scientific title: 

    Summary of trial and patient characteristics

    Cancer Type Prostate
    Trial Type Treatment
    Phase Phase III Tumour Stream Prostate
    Age Range 18 years and older Cancer Stage All stages
    Sex Male Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Prostate
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Male
    Molecular Target
    Tumour Stream Prostate
    Cancer Stage All stages
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    Phase III, randomised, double-blind trial of pembrolizumab (MK-3475) plus enzalutamde vs placebo plus enzalutamide in participants with mCRPC

    Lay Summary

    Sponsor / Cooperative group

    MSD

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Royal Adelaide Hospital Anne Milton anne.milton@sa.gov.au 08 7074 2342 Recruiting